Results 101 to 110 of about 133,265 (260)
Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack +16 more
wiley +1 more source
Purpose of review: Long-term survival of liver transplant recipients is threatened by increased rates of de-novo malignancy and recurrence of hepatocellular carcinoma (HCC), both events tightly related to immunosuppression.
Burroughs, AK +2 more
core
Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors
Summary Immune checkpoint inhibitors (ICIs) have shown to be effective in the treatment of Hodgkin lymphoma (HL). ICI treatment is associated with the occurrence of a series of immune‐related adverse events (irAEs). We conducted an ambispective observational study on 96 patients with relapsed/refractory HL treated with ICIs to determine the incidence ...
Lisa Argnani +9 more
wiley +1 more source
Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George +13 more
wiley +1 more source
Multimodal integration of sex‐ and age‐related immune‐gene signatures with baseline tumor burden (TMTV1) improves prediction of treatment response in adolescents and young adults with classical Hodgkin lymphoma. Summary The study investigates how sex and age influence treatment response in paediatric, adolescent and young adult (AYA) classical Hodgkin ...
Valli De Re +54 more
wiley +1 more source
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin +27 more
wiley +1 more source
Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants (n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified ...
Yolanda Benavente +56 more
wiley +1 more source
Summary Mature T‐cell lymphomas comprise a heterogeneous group of aggressive non‐Hodgkin lymphomas with limited therapeutic options in the relapsed or refractory setting. Among them, anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) represents a biologically distinct subtype driven by constitutive activation of ALK fusion ...
Santino Caserta +13 more
wiley +1 more source
Intraosseous Non-Hodgkin Lymphoma Mimicking a Periapical Lesion. [PDF]
Cunha LTMQ +6 more
europepmc +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source

